加拿大心力衰竭住院的经济负担:基于人口的研究
Emily E Ellis1,2, Hena Quereshi1,2, Douglas C Dover1,2
1Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
CJC open
|April 4, 2025
概括
加拿大的心力衰竭住院病例正在上升,耗资数十亿美元. 未来的预测表明,心力衰竭 (HF) 发作和相关的医疗保健费用显著增加,需要积极的卫生系统规划.
科学领域:
- 心脏病学 心脏病学
- 卫生经济学 卫生经济学
- 公共卫生 公共卫生
背景情况:
- 心力衰竭 (HF) 是死亡率,发病率和大量医疗资源利用的主要原因.
- 了解高风住院的经济影响对于加拿大医疗保健规划至关重要.
研究的目的:
- 检查2010/2011年至2018/2019年期间加拿大心力衰竭患者住院费用.
- 为了估计未来的HF住院费用到2039/2040.
主要方法:
- 分析了在2010/2011年至2018/2019年期间首次诊断为HF的住院记录.
- 总住院费用和每位患者费用的计算,调整为2022 CAD$.
- 使用通用线性模型和加拿大统计局的人口数据,预测未来的HF住院病例和成本.
主要成果:
- 在2010/2011年至2018/2019年期间,HF住院病例从43,114例增加到54,743例.
- 在同一时期,HF的住院总费用从6.843亿美元增加到7.76亿美元,累计达到66.5亿美元.
- 预计2019/2020年至2039/2040年期间有169万次HF住院病例,估计成本为195亿美元.
结论:
- 心力衰竭给加拿大医疗保健系统带来了巨大的和日益增长的经济负担.
- 需要有效的卫生系统规划和政策干预,以减轻未来的高频率相关成本.
- 战略应侧重于减少住院障碍,促进有效的HF疗法,并加强社区医疗服务.
相关概念视频
Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
Imbalances in Cardiac Output
1.2K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.2K
Heart Failure Drugs: β-Blockers
284
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
284
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
331
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
331
Heart Failure Drugs: Diuretics
298
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
298
Heart Failure Drugs: Inotropic Agents
445
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
445


